GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2026, recommended Final Dividend of Rs. 57 per equity share.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported strong FY26 results with standalone revenue of Rs. 3,79,020 Lakhs (up 1.8% YoY) and profit after tax of Rs. 1,01,182 Lakhs (up 10.1% YoY). Consolidated PAT stood at Rs. 1,03,598 Lakhs, up 11.7% from Rs. 92,758 Lakhs in FY25. The Board recommended a final dividend of Rs. 57 per equity share (face value Rs. 10), representing a 5.6% increase from Rs. 54 per share in FY25. The record date for dividend entitlement is May 29, 2026, and payment will be made from July 1, 2026, subject to shareholder approval at the 101st AGM on June 30, 2026.
The dividend increase signals management confidence in sustained profitability and cash generation. With strong cash reserves (standalone cash balance of Rs. 106.6 billion), the company can comfortably fund the higher payout. This positive earnings surprise and dividend hike could provide support to the stock price.